Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia added to standard anticoagulation in pregnant women with antiphospholipid syndrome
MOH_2020-03-24_008794Phase 2Not yet recruiting
- Sponsor
- פרופ' מרב לידר
- Start
- Mar 2020
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of certolizumab pegol in antiphospholipid syndrome (APS), sponsored by פרופ' מרב לידר. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
certolizumab pegol
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on MOH_2020-03-24_008794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-03-24_008794.